StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note released on Friday. The brokerage issued a hold rating on the medical research company’s stock.

CTSO has been the subject of several other research reports. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Wednesday, August 14th. EF Hutton Acquisition Co. I raised Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th.

Cytosorbents Trading Down 1.0 %

Shares of Cytosorbents stock opened at $1.04 on Friday. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $2.15. The firm has a market cap of $56.48 million, a PE ratio of -1.76 and a beta of 0.51. The stock has a fifty day moving average price of $1.16 and a 200-day moving average price of $1.00. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.12 and a quick ratio of 1.71.

Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. Cytosorbents had a negative return on equity of 131.84% and a negative net margin of 68.70%. The firm had revenue of $9.89 million during the quarter, compared to analyst estimates of $9.73 million. During the same period last year, the firm posted ($0.14) EPS. Equities research analysts anticipate that Cytosorbents will post -0.32 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. CM Management LLC boosted its stake in Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after purchasing an additional 25,000 shares during the period. Atomi Financial Group Inc. bought a new stake in shares of Cytosorbents during the 3rd quarter valued at about $51,000. Sargent Investment Group LLC boosted its position in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares during the last quarter. Finally, Avenir Corp boosted its position in shares of Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after acquiring an additional 121,294 shares during the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.